Trial Profile
A trial to study the low dose effect of rituximab in patients with primary Membranous glomerulonephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Membranous glomerulonephritis
- Focus Therapeutic Use
- 04 Aug 2016 New trial record
- 06 Jul 2016 Results published in the Nephrology Dialysis Transplantation